WMT

118.87

-1.78%↓

COST

976.01

-0.61%↓

KO

80.81

-2.19%↓

PG

149.92

+0.35%↑

PM

181.4

-1.48%↓

WMT

118.87

-1.78%↓

COST

976.01

-0.61%↓

KO

80.81

-2.19%↓

PG

149.92

+0.35%↑

PM

181.4

-1.48%↓

WMT

118.87

-1.78%↓

COST

976.01

-0.61%↓

KO

80.81

-2.19%↓

PG

149.92

+0.35%↑

PM

181.4

-1.48%↓

WMT

118.87

-1.78%↓

COST

976.01

-0.61%↓

KO

80.81

-2.19%↓

PG

149.92

+0.35%↑

PM

181.4

-1.48%↓

WMT

118.87

-1.78%↓

COST

976.01

-0.61%↓

KO

80.81

-2.19%↓

PG

149.92

+0.35%↑

PM

181.4

-1.48%↓

Search

Compass Pathways Plc ADR

Open

11.9 -1.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.03

Max

12.26

Belangrijke statistieken

By Trading Economics

Inkomsten

185M

91M

EPS

-0.3

Werknemers

156

EBITDA

139M

93M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+94.54% upside

Dividenden

By Acuity

Volgende Winsten

30 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

211M

1.5B

Vorige openingsprijs

13.47

Vorige sluitingsprijs

11.9

Compass Pathways Plc ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
help-icon Live chat